Toxicity and Long-Term Outcomes of Dose-Escalated Intensity Modulated Radiation Therapy to 74Gy for Localised Prostate Cancer in a Single Australian Centre

Cancers

Joseph Sia¹  Daryl Lim Joon¹  Angela Viotto¹  Carmel Mantle¹  George Quong¹  Aldo Rolfo¹  Morikatsu Wada¹  Nigel Anderson¹  Maureen Rolfo¹ 

[1] Austin Health Radiation Oncology Centre, Heidelberg Repatriation Hospital, 300 Waterdale Road, Heidelberg West, Victoria 3081, Australia; E-Mails:

关键词: dose escalation;    IMRT;    late effects;    prostate cancer;    toxicity;    radiation;   

DOI  :  10.3390/cancers3033419

来源: mdpi

【 摘 要 】

To report the toxicity and long-term outcomes of dose-escalated intensity-modulated radiation therapy (IMRT) for patients with localised prostate cancer.

From 2001 to 2005, a total of 125 patients with histologically confirmed T1-3N0M0 prostate cancer were treated with IMRT to 74Gy at the Austin Health Radiation Oncology Centre. The median follow-up was 5.5 years (range 0.5–8.9 years). Biochemical prostate specific antigen (bPSA) failure was defined according to the Phoenix consensus definition (absolute nadir + 2ng/mL). Toxicity was scored according to the RTOG/EORTC criteria. Kaplan-Meier analysis was used to calculate toxicity rates, as well as the risks of bPSA failure, distant metastases, disease-specific and overall survival, at 5 and 8-years post treatment.

All patients completed radiotherapy without any treatment breaks. The 8-year risks of ≥ Grade 2 genitourinary (GU) and gastrointestinal (GI) toxicity were 6.4% and 5.8% respectively, and the 8-year risks of ≥ Grade 3 GU and GI toxicity were both < 0.05%. The 5 and 8-year freedom from bPSA failure were 76% and 58% respectively. Disease-specific survival at 5 and 8 years were 95% and 91%, respectively, and overall survival at 5 and 8 years were 90% and 71%, respectively.

These results confirm existing international data regarding the safety and efficacy of dose-escalated intensity-modulated radiation therapy for localised prostate cancer within an Australian setting.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.